Governor Corbett Announces 67 New Jobs with Spark Therapeutics
Expansion in Philadelphia
in October 2013 with Support of the Children’s Hospital of Philadelphia
Harrisburg – Continuing
to advance his JOBS1st PA initiative, Governor Tom Corbett today announced that
Spark Therapeutics will expand operations at a new building at the University
City Science Center, a move that will create 67 new high-paying jobs in
are leading the new wave of scientific transformation through innovative
research and technology,” Corbett said. “My administration is proud to partner
with companies like Spark Therapeutics who dare to dream and define
Pennsylvania as a national life sciences leader. Today we celebrate the growth
and success of an innovative Pennsylvania start-up that will create 67 new
Therapeutics is a clinical-stage biotechnology company developing potentially
curative gene therapies for a wide variety of debilitating diseases. The
company will lease a 28,000-square-foot office, lab and manufacturing space in
Philadelphia. The company will make significant investments at the new site and
has committed to creating at least 67 new jobs and retaining five more
positions over the next three years.
deeply committed to the Philadelphia life sciences community, particularly
since many of our scientific co-founders and advisors represent world-class
local institutions. We are excited to add more local talent to our team as we
continue to grow, and appreciate the support of the Governor and the Mayor as
we work to deliver potentially transformative medicines to patients in need,”
said Jeffrey D. Marrazzo, co-founder, president and CEO of Spark.
Therapeutics is a great example of how innovations developed at our anchor
institutions can develop therapies that improve lives," said Philadelphia
Mayor Michael A. Nutter. "The commitment from the Children’s Hospital of
Pennsylvania to support companies like Spark Therapeutics continues to keep
Philadelphia’s life-sciences at the forefront of national advancements in
medicine. We’re excited and proud that Spark Therapeutics started here, is
staying here at the University City Science Center, and will grow here in
received a funding proposal from the Department of Community and Economic
Development including a $150,000 Pennsylvania First Program grant that
facilitates investment and job creation and $201,000 in Job Creation Tax
has also been encouraged to apply for the funding offer as well as a
low-interest loan including $1.6 million from the Machinery and Equipment Loan
was coordinated by the Governor’s Action Team, an experienced group of economic
development professionals who report directly to the Governor and work with
businesses that are considering locating or expanding in Pennsylvania in
collaboration with Select Greater Philadelphia.
Greater Philadelphia was happy to play an advisory role and to make key
introductions to help Spark Therapeutics obtain the information and contacts
necessary to make the best business decision for growing their business in
Greater Philadelphia.” said Jeanne Nevelos, Vice President, Business
Development, Select Greater Philadelphia.
launched in October 2013 with a $50 million capital commitment from the
Children’s Hospital of Philadelphia. The company’s lead gene therapy candidate,
for RPE65-related blindness, is currently in Phase 3 clinical trials
with the potential to be the first approved gene therapy in the U.S., and the
first treatment to address the significant unmet needs of patients living with
blindness due to inherited retinal dystrophies.
information on Spark Therapeutics, visit www.sparktx.com.
2012, Gov. Corbett launched JOBS1st PA as a comprehensive roadmap to economic
recovery that harnessed the state’s resources and talents to prioritize
private-sector job creation and retention. Today, Pennsylvania's unemployment
rate stands at a five-year low and jobs have been growing on a consistent basis
for nearly four years.
information about Corbett’s commitment to job creation, visit www.pa.gov.
Caras, Governor’s Office; 717-783-1116
Kensinger, DCED; 717-783-1132